We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Unum Therapeutics Inc | NASDAQ:UMRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.35 | 2.35 | 2.40 | 0 | 01:00:00 |
“The clinical data presented at this year’s ASH include updates from the ongoing Phase 1 trial of ACTR707 in combination with rituximab and the completed Phase 1 trial of ACTR087 in combination with rituximab, both conducted in patients with relapsed or refractory CD20+ NHL,” said Jessica Sachs, M.D., Chief Medical Officer of Unum. “The data with ACTR707 at this year’s ASH continue to support further dose-escalation in this Phase 1 trial and provide proof-of-mechanism for the ACTR platform that we are also applying in our lead program, a Phase 1 trial with ACTR707 in combination with trastuzumab in HER2+ solid tumor cancers. Safety data from the Phase 1 trial with ACTR087 presented at this year’s ASH provide learnings that are being applied to ongoing clinical trials with ACTR T cell products.
Poster (#1587) Title: “Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination With Rituximab in Subjects with Relapsed or Refractory CD20+ Non-Hodgkin Lymphoma”
Table 1: ACTR707 Preliminary Phase 1 trial clinical response results in r/r NHL (Cohorts 1-4) | |||||
Clinical Response (1) | Cohort 1 (n=6) | Cohort 2 (n=3) | Cohort 3 (n=5) | Cohort 4 (n=6) | Cohorts 1-4 (n=20) |
Complete Response | 3 | 1 | 2 | 2 | 40% (8/20) |
Partial Response | 0 | 1 | 2 | 0 | 15% (3/20) |
Stable Disease | 0 | 0 | 0 | 1 | 5% (1/20) |
Indeterminate Response | 1 | 0 | 0 | 0 | 5% (1/20) |
Progressive Disease | 2 | 1 | 1 | 3 | 35% (7/20) |
Overall Response Rate | 50% (3/6) | 67% (2/3) | 80% (4/5) | 33% (2/6) | 55% (11/20) |
ACTR707+T cells administered, target per patient (range) | 25M (23-38M) | 40M (30-50M) | 55M (45-55M) | 80M (65-100M) | |
(1) Data cutoff as of Nov 2019 | |||||
Table 2: ACTR707 Preliminary Phase 1 trial safety results in r/r NHL (Cohorts 1-4) | ||||
Safety Event (1) | Cohort 1 (n=6) | Cohort 2 (n=3) | Cohort 3 (n=5) | Cohort 4 (n=6) |
Dose-limiting toxicities | 0 | 0 | 0 | 0 |
Severe neurologic events (> Grade 3) | 0 | 0 | 0 | 0 |
CRS (any grade) | 0 | 0 | 0 | 0 |
ACTR707-related SAEs | 1 | 2 | 0 | 1 |
febrile neutropenia | 1 | 1 | 0 | 1 |
cytopenia | 0 | 1 | 0 | 0 |
(1) Data cutoff as of Nov 2019 | ||||
Additional details about the ATTCK-20-03 Phase 1 trial can be found here.
Oral Presentation Title (#244): “A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma”
Following the decision in 2018 to prioritize ACTR707 over ACTR087 for future development in r/r NHL and solid tumors, Unum completed enrollment in the ATTCK-20-2 trial, a Phase 1, multicenter, open-label, single-arm, dose-escalating trial evaluating ACTR087 in combination with rituximab in patients with r/r CD20+ NHL.
Additional details about the ATTCK-20-2 Phase 1 trial can be found here.
About Unum TherapeuticsUnum Therapeutics is a clinical-stage biopharmaceutical company focused on developing curative cell therapies to treat a broad range of cancer patients. Unum’s novel proprietary technologies include Antibody-Coupled T cell Receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immune responses, and Bolt-On Chimeric Receptor (BOXR), designed to improve the functionality of engineered T cells by incorporating a “bolt-on” transgene to overcome resistance of the solid tumor microenvironment to T cell attack. Unum has multiple programs in Phase 1 clinical and preclinical testing, including: ACTR707 used in combination with trastuzumab in adult patients with HER2+ advanced cancer and used in combination with rituximab in adult patients with r/r NHL; and BOXR1030 expressing the GOT2 transgene and targeting GPC3+ solid tumor cancers. The Company is headquartered in Cambridge, MA.
Follow Unum Therapeutics on social media: @UnumRx, and LinkedIn.
Forward looking Statements
This press release contains forward-looking statements including, without limitation, statements regarding our future expectations, plans and prospects, including projections regarding future revenues and financial performance, our long-term growth, enrollment and results for our preclinical and clinical activities, the development of our product candidates, including the ACTR product candidates and the BOXR platform and product candidates, and the anticipated timing and success of any of our preclinical studies, clinical trials and regulatory filings, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, as amended. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Investor Contact: Stern Investor Relations, Inc. Stephanie Ascher, 212-362-1200 stephanie@sternir.com
Media Contact:Lissette Steele, 202-930-4762lsteele@vergescientific.com
1 Year Unum Therapeutics Chart |
1 Month Unum Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions